autologous immunoglobulin idiotype-klh conjugate vaccine
Vaccineexperimental
Clinical trial activity
9 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
8
Phase 3
3
Phase 4
0
Earliest trial started Mar 1, 1996 (NCT00002787)
Timeline
Indications
Mechanism of action
- T cellImmunity, active
T cell immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous immunoglobulin idiotype-klh conjugate vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00621036 | Phase 2 | Nov 1, 2007 | The University of Texas, Dallas |
| NCT00510471 | Phase 2 | May 1, 2007 | Genitope Corporation |
| NCT00324831 | Phase 3 | May 10, 2006 | Favrille |
| NCT00104819 | Phase 2 | Sep 1, 2004 | Favrille, National Cancer Institute (NCI) |
| NCT00258336 | Phase 2 | Aug 1, 2004 | Favrille |
| NCT00089115 | Phase 3 | Jul 1, 2004 | Favrille |
| NCT00071955 | Phase 2 | Mar 1, 2003 | Genitope Corporation |
| NCT00017290 | Phase 3 | Nov 1, 2000 | Genitope Corporation |
| NCT00002787 | Phase 1 | Mar 1, 1996 | National Cancer Institute (NCI), University of Washington |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Favrille | For profit | 4 | 4 | 2 | 2004 |
| Genitope Corporation | For profit | 3 | 3 | 2 | 2000 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 1996 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 1 | 1 | 2007 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 1996 |
5 organizations
Page 1 / 1